Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression

Molecular Therapy

Volumn 20, Issue 9, 2012, Pages 1689-1698

  Perez, Omar D ^a   Logg, Christopher R ^b   Hiraoka, Kei ^b   Diago, Oscar ^a   Burnett, Ryan ^a   Inagaki, Akihito ^b   Jolson, Dawn ^a   Amundson, Karin ^a   Buckley, Taylor ^a   Lohse, Dan ^a   Lin, Amy ^a   Burrascano, Cindy ^a   Ibanez, Carlos ^a   Kasahara, Noriyuki ^b   Gruber, Harry E ^a   Jolly, Douglas J ^a  

^a Tocagen Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; VOCIMAGENE AMIRETROREPVEC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STABILITY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC STABILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TRANSGENE; TUMOR REGRESSION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL GENETICS; VIRUS LOAD; VIRUS REPLICATION;

AMPHOTROPIC MURINE LEUKEMIA VIRUS; ANIMALIA;

EID: 84867077136     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.83     Document Type: Article

References (37)

1. Kelly, E and Russell, SJ (2007). History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15: 651-659. (Pubitemid 46431984)
2. Stanford, MM, Bell, JC and Vähä-Koskela, MJ (2010). Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev 21: 177-183.
3. Barral, PM, Sarkar, D, Su, ZZ, Barber, GN, DeSalle, R, Racaniello, VR et al. (2009). Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity. Pharmacol Ther 124: 219-234.
4. Parato, KA, Lichty, BD and Bell, JC (2009). Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther 11: 13-21.
5. Naik, S and Russell, SJ (2009). Engineering oncolytic viruses to exploit tumor specifc defects in innate immune signaling pathways. Expert Opin Biol Ther 9: 1163-1176.
6. Alain, T, Lun, X, Martineau, Y, Sean, P, Pulendran, B, Petroulakis, E et al. (2010). Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 107: 1576-1581.
7. Diallo, JS, Le Boeuf, F, Lai, F, Cox, J, Vaha-Koskela, M, Abdelbary, H et al. (2010). A high-throughput pharmacoviral approach identifes novel oncolytic virus sensitizers. Mol Ther 18: 1123-1129.
8. Le Boeuf, F, Diallo, JS, McCart, JA, Thorne, S, Falls, T, Stanford, M et al. (2010). Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18: 888-895.
9. Senzer, NN, Kaufman, HL, Amatruda, T, Nemunaitis, M, Reid, T, Daniels, G et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771.
10. Logg, CR, Tai, CK, Logg, A, Anderson, WF and Kasahara, N (2001). A uniquely stable replication-competent retrovirus vector achieves effcient gene delivery in vitro and in solid tumors. Hum Gene Ther 12: 921-932. (Pubitemid 32681856)
11. Paar, M, Klein, D, Salmons, B, Günzburg, WH, Renner, M and Portsmouth, D (2009). Infuence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors. BMC Mol Biol 10: 8.
12. Duerner, LJ, Schwantes, A, Schneider, IC, Cichutek, K and Buchholz, CJ (2008). Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue. Gene Ther 15: 1500-1510.
13. Solly, SK, Trajcevski, S, Frisén, C, Holzer, GW, Nelson, E, Clerc, B et al. (2003). Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 10: 30-39. (Pubitemid 36222074)
14. Dalba, C, Klatzmann, D, Logg, CR and Kasahara, N (2005). Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther 5: 655-667. (Pubitemid 43009509)
15. Tai, CK, Wang, WJ, Chen, TC and Kasahara, N (2005). Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival beneft in experimental glioma. Mol Ther 12: 842-851. (Pubitemid 41614479)
16. Wang, W, Tai, CK, Kershaw, AD, Solly, SK, Klatzmann, D, Kasahara, N et al. (2006). Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 20: E25.
17. Hlavaty, J, Jandl, G, Liszt, M, Petznek, H, König-Schuster, M, Sedlak, J et al. (2011). Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol 102: 59-69.
18. Brandes, AA, Tosoni, A, Franceschi, E, Reni, M, Gatta, G and Vecht, C (2008). Glioblastoma in adults. Crit Rev Oncol Hematol 67: 139-152.
19. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
20. Block, ER and Bennett, JE (1972). Pharmacological studies with 5-fuorocytosine. Antimicrob Agents Chemother 1: 476-482.
21. Menei, P, Capelle, L, Guyotat, J, Fuentes, S, Assaker, R, Bataille, B et al. (2005). Local and sustained delivery of 5-fuorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 56: 242-8; discussion 242.
22. Miller, CR, Williams, CR, Buchsbaum, DJ and Gillespie, GY (2002). Intratumoral 5-fuorouracil produced by cytosine deaminase/5-fuorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 62: 773-780. (Pubitemid 34126953)
23. Cascino, TL, Veeder, MH, Buckner, JC, O'Fallon, JR, Wiesenfeld, M, Levitt, R et al. (1996). Phase II study of 5-fuorouracil and leucovorin in recurrent primary brain tumor. J Neurooncol 30: 243-246. (Pubitemid 26377548)
24. Korkegian, A, Black, ME, Baker, D and Stoddard, BL (2005). Computational thermostabilization of an enzyme. Science 308: 857-860. (Pubitemid 40629266)
25. Logg, CR, Logg, A, Matusik, RJ, Bochner, BH and Kasahara, N (2002). Tissue-specifc transcriptional targeting of a replication-competent retroviral vector. J Virol 76: 12783-12791. (Pubitemid 35386962)
26. Ostertag, D, Amundson, KK, Lopez Espinoza, F, Martin, B, Buckley, T, Galvão da Silva, AP et al. (2012). Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fuorocytosine to 5-fuorouracil using a nonlytic retroviral replicating vector. Neuro-oncology 14: 145-159.
27. Wang, WJ, Tai, CK, Kasahara, N and Chen, TC (2003). Highly effcient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 14: 117-127. (Pubitemid 36418816)
28. Kimura, T, Hiraoka, K, Kasahara, N and Logg, CR (2010). Optimization of enzymesubstrate pairing for bioluminescence imaging of gene transfer using Renilla and Gaussia luciferases. J Gene Med 12: 528-537.
29. Erbs, P, Regulier, E, Kintz, J, Leroy, P, Poitevin, Y, Exinger, F et al. (2000). In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 60: 3813-3822. (Pubitemid 32204573)
30. Bourbeau, D, Lavoie, G, Nalbantoglu, J and Massie, B (2004). Suicide gene therapy with an adenovirus expressing the fusion gene CD: : UPRT in human glioblastomas: different sensitivities correlate with p53 status. J Gene Med 6: 1320-1332. (Pubitemid 40287704)
31. Suttle, D P, Bugg, BY, Winkler, JK and Kanalas, JJ (1988). Molecular cloning and nucleotide sequence for the complete coding region of human UMP synthase. Proc Natl Acad Sci USA 85: 1754-1758. (Pubitemid 24315760)
32. Sakamoto, E, Nagase, H, Kobunai, T, Oie, S, Oka, T, Fukushima, M et al. (2007). Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the effcacy of 5-fuorouracil. Biochem Biophys Res Commun 363: 216-222. (Pubitemid 47432917)
33. Logg, CR, Logg, A, Tai, CK, Cannon, PM and Kasahara, N (2001). Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary. J Virol 75: 6989-6998. (Pubitemid 32641586)
34. Paar, M, Schwab, S, Rosenfellner, D, Salmons, B, Günzburg, WH, Renner, M et al. (2007). Effects of viral strain, transgene position, and target cell type on replication kinetics, genomic stability, and transgene expression of replication-competent murine leukemia virus-based vectors. J Virol 81: 6973-6983. (Pubitemid 46986633)
35. Johnson, AJ, Ardiani, A, Sanchez-Bonilla, M and Black, ME (2011). Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications. Cancer Gene Ther 18: 533-542.
36. Salaün, C, Gyan, E, Rodrigues, P and Heard, JM (2002). Pit2 assemblies at the cell surface are modulated by extracellular inorganic phosphate concentration. J Virol 76: 4304-4311. (Pubitemid 34309566)
37. Pan, J, Zhong, C, Chang, Z and Roy-Burman, P (2003). A potential therapeutic strategy to combat leukemia virus infection. Cancer Biol Ther 2: 92-99.